Strategic Regulatory Planning Flashcards

In EU strategic planning, what is the strategic rationale for using the 'Article 8(3)' full application pathway versus the 'Article 10' generic pathway?

Answer: Article 8(3) is used for new active substances requiring a complete independent dossier of safety and efficacy

Article 8(3) requires a complete, independent application for new active substances where no reference product exists to rely upon, making it the pathway for true innovator products in the EU.

A company is planning regulatory strategy for a biosimilar. Which study is uniquely required compared to a small-molecule generic?

Answer: Comparative clinical immunogenicity and pharmacokinetic/pharmacodynamic studies versus the reference biologic

Biosimilar development requires comparative PK/PD and immunogenicity studies versus the reference biologic because complex biological molecules cannot be characterized as identical through analytical testing alone.

What does 'regulatory feasibility assessment' accomplish in early strategic planning?

Answer: It evaluates whether a product concept can meet regulatory requirements in target markets before significant investment

A regulatory feasibility assessment conducted early identifies potential development blockers, pathway options, and jurisdictional requirements before substantial resources are committed.

When a regulatory strategy calls for pursuing Priority Review in the US, what additional planning is required compared to Standard Review?

Answer: More intensive FDA meeting interactions and readiness for a 6-month rather than 12-month review clock

Priority Review compresses FDA's review goal to 6 months (versus 10-12 for Standard), requiring the regulatory team to be prepared for faster agency feedback cycles and accelerated internal decision-making.

Which scenario best illustrates a 'regulatory arbitrage' strategy?

Answer: Launching first in a jurisdiction with a more flexible or faster pathway, using that approval to support other filings

Regulatory arbitrage exploits differences in regional regulatory pathways or timelines to gain early market access and leverage that approval reference for subsequent global filings.

A product is approved in the US but the sponsor plans EU submission. Which ICH guideline is most relevant for planning additional safety studies to address European requirements?

Answer: ICH E1 (Population Exposure) or ICH S6 for specific product types addressing safety database size

ICH E1 addresses the extent of patient exposure needed to assess clinical safety, helping sponsors determine if their US safety database is sufficient for EU submission or if additional data is needed.

In strategic regulatory planning, 'lifecycle management' (LCM) refers to:

Answer: Systematic planning of post-approval changes, new indications, and line extensions to extend commercial value

Regulatory LCM encompasses proactively planning formulation changes, new indications, pediatric extensions, and other post-approval strategies that sustain and grow the product's market position.